Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention

被引：7

作者：

Ambrose, JA ^{[1
]}

Doss, R ^{[1
]}

Geagea, JPM ^{[1
]}

Hawkey, MC ^{[1
]}

Duvuri, S ^{[1
]}

Giedd, K ^{[1
]}

Dominguez, A ^{[1
]}

Coppola, J ^{[1
]}

Nguyen, TH ^{[1
]}

Palla, V ^{[1
]}

Barua, RS ^{[1
]}

Saha, DC ^{[1
]}

机构：

[1] St Vincents Hosp & Med Ctr, Dept Med, Div Cardiol, New York, NY 10011 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2001年 / 87卷 / 10期

关键词：

D O I：

10.1016/S0002-9149(01)01506-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 61 patients undergoing coronary intervention, the antithrombin activity of standard dose abciximab (n = 31) and weight-adjusted heparin was compared with the RE-STORE dose tirofiban (n = 30) and the same dose of weight-adjusted heparin. Serial measurements of the activated clotting time, prothrombin fragment F1.2, and GP IIb/IIIa receptor occupancy were obtained in a standardized protocol. There was no difference in antithrombin activity between these 2 compounds, suggesting that this activity represents a class effect related to inhibition of the GP IIb/IIa receptor alone.

引用

页码：1231 / +

页数：4

共 14 条

[1] In vivo demonstration of an antithrombin effect of Abciximab [J].

Ambrose, JA ;

Hawkey, M ;

Badimon, JJ ;

Coppola, J ;

Geagea, JP ;

Rentrop, KP ;

Domiguez, A ;

Duvvuri, S ;

Elmquist, T ;

Arias, J ;

Doss, R ;

Dangas, G .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (02) :150-152

[2]

BYZOVA TV, 1997, J BIOL CHEM, V272, P183

[3] Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition - Implications for a potential anticoagulant effect of abciximab [J].

Dangas, G ;

Badimon, JJ ;

Coller, BS ;

Fallon, JT ;

Sharma, SK ;

Hayes, RM ;

Meraj, P ;

Ambrose, JA ;

Marmur, JD .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (08) :1342-1349

[4]

*EPIC INV, 1994, NEW ENGL J MED, P184

[5]

Hanrath P, 1997, CIRCULATION, V96, P1445

[6] Antithrombotic effects of abciximab [J].

Hayes, R ;

Chesebro, JH ;

Fuster, V ;

Dongas, G ;

Fallon, JT ;

Sharma, SK ;

Coller, BS ;

Badimon, L ;

Marmur, JD ;

Badimon, JJ .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (10) :1167-1172

[7] Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention [J].

Kereiakes, DJ ;

Broderick, TM ;

Roth, EM ;

Whang, D ;

Shimshak, T ;

Runyon, JP ;

Hattemer, C ;

Schneider, J ;

Lacock, P ;

Mueller, M ;

Abbottsmith, CW .

AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (04) :391-395

[8]

Musial J, 1997, THROMB RES, V85, P367

[9]

Rao AK, 1999, THROMB HAEMOSTASIS, V82, P140

[10] Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody - Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ''clinical restenosis'' [J].

Reverter, JC ;

Beguin, S ;

Kessels, H ;

Kumar, R ;

Hemker, HC ;

Coller, BS .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (03) :863-874

← 1 2 →